AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30413383 — intervention group
Group type: COMPARATOR
Intervention: Upfront debulking surgery (stage IV)
Number of subjects: 1220
Study 27117874 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 12 mg oral dexamethasone with 4 days of placebo
Number of subjects: 376
Study 27117874 — intervention group
Group type: COMPARATOR
Intervention: 5-day course of oral prednisone 60 mg a day
Number of subjects: 376
Study 25250614 — intervention group
Group type: EXPERIMENTAL
Intervention: LX‐A
Number of subjects: 20
Study 25250614 — intervention group
Group type: EXPERIMENTAL
Intervention: LX‐P
Number of subjects: 20
Study 23013843 — intervention group
Group type: EXPERIMENTAL
Intervention: DiAlert intervention (two group sessions)
Number of subjects: 21
Study 20714145 — intervention group
Group type: EXPERIMENTAL
Intervention: Biapenem 300 mg
Number of subjects: 216
Study 20714145 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg/500 mg
Number of subjects: 216
Study 17094981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ACTH
Number of subjects: 15
Study 17094981 — intervention group
Group type: COMPARATOR
Intervention: None (Control group)
Number of subjects: 15
Study 16152759 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN alpha 2a (180 microg per week) and RBV (1000‐1200 mg daily)
Number of subjects: 198
Study 12225445 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + acamprosate
Number of subjects: 50
Study 12225445 — intervention group
Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 50
Study 10363624 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg without antacid
Number of subjects: 12
Study 10363624 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg with antacid (concomitantly)
Number of subjects: 12
Study 10363624 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg one hour after antacid administration
Number of subjects: 12
Study 7549753 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with four nutrients (vitamin A, riboflavin, zinc, and selenium), one capsule twice a week for 1 year
Number of subjects: 298
Study 7549753 — intervention group
Group type: COMPARATOR
Intervention: Placebo, one capsule twice a week for 1 year
Number of subjects: 298
Study 2250565 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 8
Study 2250565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2250565 — intervention group
Group type: COMPARATOR
Intervention: Methysergide
Number of subjects: 8
Study 6767186 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 11
Study 6767186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31943717 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR with periprocedural anticoagulation with unfractionated heparin
Number of subjects: 800
Study 31201072 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 72
Study 31201072 — intervention group
Group type: COMPARATOR
Intervention: Standard consent
Number of subjects: 72
Study 28235795 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored parenting support program (Ladnaan) combined with the parenting program Connect, delivered over 12 weeks, 1 to 2 hours each week in groups of 12 to 17 parents.
Number of subjects: 120
Study 28235795 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 120
Study 26066736 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (75 mg/m²) and ifosfamide (2.5 g/m²/d) on days 1-3 with mesna 500 mg/m²/dose
Number of subjects: 80
Study 26066736 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (900 mg/m² on days 1, 8) and docetaxel (100 mg/m² on day 8)
Number of subjects: 80
Study 26066736 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and ifosfamide (AI)
Number of subjects: 80
Study 26066736 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and docetaxel (GD)
Number of subjects: 80
Study 23986139 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative learning
Number of subjects: 54
Study 23986139 — intervention group
Group type: COMPARATOR
Intervention: Traditional pre‐clinical teaching
Number of subjects: 54
Study 21129744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (6 home visits 2-8 weeks postpartum)
Number of subjects: 295
Study 21129744 — intervention group
Group type: COMPARATOR
Intervention: Control (1 planned visit)
Number of subjects: 295
Study 19186958 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol provided scaling and root planing
Number of subjects: 303
Study 19186958 — intervention group
Group type: COMPARATOR
Intervention: Community care
Number of subjects: 303
Study 19186958 — intervention group
Group type: EXPERIMENTAL
Intervention: Any preventive or periodontal care
Number of subjects: 303
Study 19186958 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 303
Study 17891452 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping (group II); 50 patients with 69 PVCs.
Number of subjects: 100
Study 17891452 — intervention group
Group type: COMPARATOR
Intervention: Conventional mapping (group I); 50 patients with 65 PVCs.
Number of subjects: 100
Study 15622454 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG 7909 (0.125, 0.5, or 1.0 mg)
Number of subjects: 0
Study 15622454 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 0
Study 11260410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (FLU) 40 mg/day
Number of subjects: 36
Study 11260410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 36
Study 9488586 — intervention group
Group type: EXPERIMENTAL
Intervention: Predisposing factors (benefits, motivation, knowledge; Cronbach alpha = 0.50)
Number of subjects: 2764
Study 9488586 — intervention group
Group type: EXPERIMENTAL
Intervention: Enabling factors (barriers, norms, social support; Cronbach alpha = 0.55)
Number of subjects: 2764
Study 9488586 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of change for adopting diets lower in fat and higher in fiber/fruits and vegetables
Number of subjects: 2764
Study 9488586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake measures (fat, fiber, fruits and vegetables)
Number of subjects: 2764
Study 9488586 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression models including predisposing and enabling factors, stage of change, and covariates
Number of subjects: 2764
Study 8045978 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha MSH (2.5 mg as an iv bolus 60 min after the start of saline infusion)
Number of subjects: 8
Study 8045978 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH (ovine CRH infused at 100 micrograms/h for 3 h)
Number of subjects: 8
Study 8045978 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH plus alpha MSH (injected 60 min after the start of CRH infusion)
Number of subjects: 8
Study 8045978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3143450 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedic geriatric unit
Number of subjects: 222
Study 3143450 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic wards
Number of subjects: 222
Study 31781760 — intervention group
Group type: EXPERIMENTAL
Intervention: BSFL23
Number of subjects: 24
Study 31781760 — intervention group
Group type: EXPERIMENTAL
Intervention: BSFL29
Number of subjects: 24
Study 31781760 — intervention group
Group type: EXPERIMENTAL
Intervention: BSFL0
Number of subjects: 24
Study 31781760 — intervention group
Group type: EXPERIMENTAL
Intervention: BSFL11
Number of subjects: 24
Study 31781760 — intervention group
Group type: EXPERIMENTAL
Intervention: BSFL18
Number of subjects: 24
Study 31781760 — intervention group
Group type: EXPERIMENTAL
Intervention: Threonine, methionine, and tryptophan
Number of subjects: 24
Study 30946212 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular ganglion cell-inner plexiform layer (GCIPL) measurements
Number of subjects: 96
Study 30946212 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential retinal nerve fiber layer (cpRNFL) measurements
Number of subjects: 96
Study 30946212 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GCIPL and cpRNFL
Number of subjects: 96
Study 30946212 — intervention group
Group type: COMPARATOR
Intervention: Comparison of GCIPL and cpRNFL in inferior hemifield defect group
Number of subjects: 96
Study 28286971 — intervention group
Group type: EXPERIMENTAL
Intervention: YOMI program (five-week intervention, twice a week)
Number of subjects: 0
Study 28286971 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list condition (control group)
Number of subjects: 0
Study 26587288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronidase and local anaesthetic
Number of subjects: 70
Study 26587288 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic only (Control)
Number of subjects: 70
Study 23615640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of estradiol (E2) daily for 12 weeks
Number of subjects: 60
Study 23615640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of estradiol (E2) and 0.5 mg of norethindrone acetate (NA) daily for 12 weeks
Number of subjects: 60
Study 23615640 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 60
Study 22122887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 355
Study 22122887 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 355
Study 18955387 — intervention group
Group type: EXPERIMENTAL
Intervention: HerpeSelect HSV‐2 ELISA
Number of subjects: 120
Study 18955387 — intervention group
Group type: EXPERIMENTAL
Intervention: Kalon HSV‐2 ELISA
Number of subjects: 120
Study 18955387 — intervention group
Group type: COMPARATOR
Intervention: Western blot
Number of subjects: 120
Study 18955387 — intervention group
Group type: COMPARATOR
Intervention: Recombinant inhibition test
Number of subjects: 120
Study 16863399 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interventions by nursing students for 12 to 14 weeks
Number of subjects: 2
Study 16863399 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no telephone interventions)
Number of subjects: 2
Study 16863399 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interventions by nursing students
Number of subjects: 2
Study 15276594 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon administered three times weekly with weight-based ribavirin
Number of subjects: 661
Study 15276594 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interferon with weight-based ribavirin
Number of subjects: 661
Study 15276594 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon and ribavirin therapy
Number of subjects: 661
Study 15513442 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy
Number of subjects: 0
Study 9466164 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-8359, oral dosing up to 300 mg
Number of subjects: 0
Study 7877116 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk nonusers (thinking about using steroids)
Number of subjects: 404
Study 7877116 — intervention group
Group type: COMPARATOR
Intervention: Low-risk nonusers (not thinking about using steroids)
Number of subjects: 404
Study 7877116 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid users
Number of subjects: 404
Study 3282481 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (maximum dosage of 300 mg/d, mean dosage at week 8 of 82.8 mg/d)
Number of subjects: 108
Study 3282481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 29420150 — intervention group
Group type: EXPERIMENTAL
Intervention: LHTLH (normobaric hypoxia; 3,000 m; n=6)
Number of subjects: 18
Study 29420150 — intervention group
Group type: COMPARATOR
Intervention: LHTL (normoxia; 0 m; n=6)
Number of subjects: 18
Study 29420150 — intervention group
Group type: COMPARATOR
Intervention: LLTL (sea level with regular training only; n=6)
Number of subjects: 18
Study 27716246 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg/day)
Number of subjects: 41
Study 27716246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 25698080 — intervention group
Group type: EXPERIMENTAL
Intervention: Image of an overweight individual
Number of subjects: 262
Study 25698080 — intervention group
Group type: COMPARATOR
Intervention: Image of a thin individual
Number of subjects: 262
Study 23091174 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field at 1.5 T
Number of subjects: 41
Study 23091174 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field at 3.0 T
Number of subjects: 41
Study 23091174 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field at 7.0 T
Number of subjects: 41
Study 23091174 — intervention group
Group type: COMPARATOR
Intervention: Control condition (mock imager with no magnetic field)
Number of subjects: 41
Study 23091174 — intervention group
Group type: EXPERIMENTAL
Intervention: Static magnetic field (varying strengths)
Number of subjects: 41
Study 20691830 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (tailored information bimonthly for 2 years via telephone)
Number of subjects: 588
Study 20691830 — intervention group
Group type: COMPARATOR
Intervention: Nonbehavioral intervention (control group)
Number of subjects: 588
Study 20691830 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 588
Study 18240203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential disease‐modifying antirheumatic drug monotherapy (group 1)
Number of subjects: 508
Study 18240203 — intervention group
Group type: EXPERIMENTAL
Intervention: Step‐up combination therapy (group 2)
Number of subjects: 508
Study 18240203 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with tapered high‐dose prednisone (group 3)
Number of subjects: 508
Study 18240203 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with infliximab (group 4)
Number of subjects: 508
Study 17014731 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Nordic Walking twice a week for eight weeks under supervision of a specially trained instructor
Number of subjects: 150
Study 17014731 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic Walking for eight weeks after one training session with an instructor
Number of subjects: 150
Study 17014731 — intervention group
Group type: COMPARATOR
Intervention: Advice to stay active (one hour motivational talk)
Number of subjects: 150
Study 17014731 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised Nordic Walking
Number of subjects: 150
Study 17014731 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic Walking
Number of subjects: 150
Study 14673036 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD-HAM-TAD maintenance
Number of subjects: 832
Study 14673036 — intervention group
Group type: COMPARATOR
Intervention: S-HAM
Number of subjects: 832
Study 10069525 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin infusion (0.1 CU/kg.h) for 60 min
Number of subjects: 8
Study 10069525 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin + CCK infusion (0.5 IDU/kg.h) for 60 min
Number of subjects: 8
Study 10069525 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions
Number of subjects: 8
Study 10069525 — intervention group
Group type: COMPARATOR
Intervention: Secretin infusion
Number of subjects: 8
Study 10069525 — intervention group
Group type: COMPARATOR
Intervention: Secretin + CCK infusion
Number of subjects: 8
Study 10069525 — intervention group
Group type: COMPARATOR
Intervention: Plasma PP levels
Number of subjects: 8
Study 7501488 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene film dressing with a perimeter adhesive system applied to a randomly determined nipple, present at all times except during feeding.
Number of subjects: 50
Study 7501488 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 50
Study 2233201 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% carbohydrate‐electrolyte drink (CE)
Number of subjects: 10
Study 2233201 — intervention group
Group type: COMPARATOR
Intervention: flavored water placebo (P)
Number of subjects: 10
Study 836095 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating room with modern ventilation system utilizing HEPA type filters
Number of subjects: 156
Study 836095 — intervention group
Group type: COMPARATOR
Intervention: Surgical suite with no environmental or traffic control systems
Number of subjects: 156
Study 31359519 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin 15 mg/day
Number of subjects: 53
Study 28805758 — intervention group
Group type: EXPERIMENTAL
Intervention: noophen (γ‐amino‐β‐phenylbutyric acid hydrochloride) 15‐20 mg/kg per day (2‐3 times perorally) for 2 months
Number of subjects: 30
Study 28805758 — intervention group
Group type: EXPERIMENTAL
Intervention: noophen (γ‐amino‐β‐phenylbutyric acid hydrochloride)
Number of subjects: 30
Study 26272250 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (FA) administered i.v. 15 min before skin incision in group F.
Number of subjects: 60
Study 26272250 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered i.v. 15 min before skin incision in group C.
Number of subjects: 60
Study 25109510 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-mg darunavir tablet (test)
Number of subjects: 99
Study 25109510 — intervention group
Group type: COMPARATOR
Intervention: 2 × 400-mg darunavir tablets (reference)
Number of subjects: 99
Study 23107992 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel partner intervention program
Number of subjects: 0
Study 23107992 — intervention group
Group type: COMPARATOR
Intervention: Control intervention program
Number of subjects: 0
Study 19528850 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 18
Study 19528850 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretch (SS)
Number of subjects: 18
Study 18160686 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus bevacizumab
Number of subjects: 722
Study 18160686 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 722
Study 15117843 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 0
Study 15117843 — intervention group
Group type: COMPARATOR
Intervention: Tirofiban
Number of subjects: 0
Study 15117843 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombocytopenia
Number of subjects: 0
Study 11786587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral megestrol acetate 800 mg/d liquid suspension plus placebo
Number of subjects: 469
Study 11786587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dronabinol 2.5 mg twice a day plus placebo
Number of subjects: 469
Study 11786587 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (dronabinol and megestrol acetate)
Number of subjects: 469
Study 11786587 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Anorexia/Cachexia Therapy questionnaire
Number of subjects: 469
Study 11786587 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐item Uniscale (global QOL instrument)
Number of subjects: 469
Study 11786587 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 469
Study 9822841 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs
Number of subjects: 24
Study 9822841 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 24
Study 7926080 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (400 mg orally twice daily for 4 months)
Number of subjects: 52
Study 7926080 — intervention group
Group type: COMPARATOR
Intervention: Estrogen and progestin replacement regimen (for 4 months)
Number of subjects: 52
Study 7926080 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results
Number of subjects: 52
Study 3302093 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 63
Study 3302093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 29066587 — intervention group
Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 15
Study 29066587 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-synchronized noninvasive ventilation (ns‐NIV)
Number of subjects: 15
Study 27041263 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (prophylactic administration)
Number of subjects: 57
Study 27041263 — intervention group
Group type: COMPARATOR
Intervention: Non-flurbiprofen (control group)
Number of subjects: 57
Study 27041263 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-flurbiprofen (MTS group)
Number of subjects: 57
Study 27041263 — intervention group
Group type: COMPARATOR
Intervention: Non-flurbiprofen (non-MTS group)
Number of subjects: 57
Study 27041263 — intervention group
Group type: EXPERIMENTAL
Intervention: FloTrac sensor
Number of subjects: 57
Study 23715407 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise training
Number of subjects: 25
Study 23715407 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control group
Number of subjects: 25
Study 23221660 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroma self-foot reflexology massage
Number of subjects: 52
Study 23221660 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study 21374895 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low back pain patients
Number of subjects: 1378
Study 21374895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high disability and limitations in daily living
Number of subjects: 1378
Study 21374895 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depression
Number of subjects: 1378
Study 21374895 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic procedures and hospital or rehabilitational care
Number of subjects: 1378
Study 21374895 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall LBP care costs
Number of subjects: 1378
Study 19039821 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg)
Number of subjects: 16
Study 19039821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16